OVID

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ovid Therapeutics Inc

NASDAQ | OVID

1.78

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$116.08M

Market Cap

-

P/E Ratio

-0.5

EPS

$2.01

52 Week High

$0.24

52 Week Low

HEALTHCARE

Sector

OVID Chart

Recent Chart
Price Action

OVID Technicals

Tags:

OVID Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $566K
Total Revenue $566K
Cost Of Revenue $600K
Costof Goods And Services Sold $600K
Operating Income -$62M
Selling General And Administrative $26M
Research And Development $37M
Operating Expenses $62M
Investment Income Net -
Net Interest Income $3.9M
Interest Income $3.9M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $613K
Income Before Tax -$26M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$26M
Comprehensive Income Net Of Tax -
Ebit -$58M
Ebitda -$58M
Net Income -$26M

Revenue & Profitability

Earnings Performance

OVID Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $92M
Total Current Assets $56M
Cash And Cash Equivalents At Carrying Value $26M
Cash And Short Term Investments $26M
Inventory -
Current Net Receivables -
Total Non Current Assets $36M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $92K
Intangible Assets Excluding Goodwill $92K
Goodwill -
Investments -
Long Term Investments $21M
Short Term Investments $27M
Other Current Assets $2.9M
Other Non Current Assets -
Total Liabilities $24M
Total Current Liabilities $11M
Current Accounts Payable $3.2M
Deferred Revenue -
Current Debt -
Short Term Debt $1.3M
Total Non Current Liabilities $13M
Capital Lease Obligations $15M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $15M
Other Current Liabilities $6M
Other Non Current Liabilities -
Total Shareholder Equity $68M
Treasury Stock -
Retained Earnings -$304M
Common Stock $71K
Common Stock Shares Outstanding $71M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$56M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $613K
Capital Expenditures $71K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $55M
Cashflow From Financing $622K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$26M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $566K
Total Revenue $566K
Cost Of Revenue $600K
Costof Goods And Services Sold $600K
Operating Income -$62M
Selling General And Administrative $26M
Research And Development $37M
Operating Expenses $62M
Investment Income Net -
Net Interest Income $3.9M
Interest Income $3.9M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $613K
Income Before Tax -$26M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$26M
Comprehensive Income Net Of Tax -
Ebit -$58M
Ebitda -$58M
Net Income -$26M

OVID News

OVID Profile

Ovid Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company focused on the development of innovative therapies for neurological disorders, which represent a significant unmet medical need. With a robust pipeline targeting conditions such as epilepsy, Ovid is committed to advancing treatment options that improve patient outcomes. The company leverages its deep expertise in neurology to drive the discovery and delivery of transformative therapies, positioning itself as a leader in the biopharmaceutical landscape dedicated to enhancing the quality of life for patients and their families.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
BMNU
+8.84%
$8.18
ONMD
+30.28%
$1.85
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
ADTX
+21.01%
$3.80
DEFT
+9.35%
$1.52
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CAN
+0.75%
$0.92
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
WBD
+0.50%
$24.00
VEEE
+45.50%
$2.59
APLD
+8.66%
$27.10
AG
+12.65%
$15.22
GOOG
-0.05%
$320.12
NGD
+6.50%
$8.35
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.76%
$17.28
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
BMNU
+8.84%
$8.18
ONMD
+30.28%
$1.85
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
ADTX
+21.01%
$3.80
DEFT
+9.35%
$1.52
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CAN
+0.75%
$0.92
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
WBD
+0.50%
$24.00
VEEE
+45.50%
$2.59
APLD
+8.66%
$27.10
AG
+12.65%
$15.22
GOOG
-0.05%
$320.12
NGD
+6.50%
$8.35
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.76%
$17.28
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.